Mucopolysaccharide

Mucopolysaccharide (Glycosaminoglycan): A Comprehensive Reference

1. Identity, Nomenclature, and Chemical Nature

The most abundant heteropolysaccharides in the body are the glycosaminoglycans (GAGs), which are historically referred to as mucopolysaccharides, given that they were originally characterized in mucus membranes and mucosal exudates. In contemporary biochemistry and pharmacology, the term mucopolysaccharide is considered archaic and has been largely supplanted by glycosaminoglycan (GAG), though both terms remain in use in nutritional supplement contexts.

Glycosaminoglycans (GAGs), also known as mucopolysaccharides, are negatively charged polysaccharide compounds. They are composed of repeating disaccharide units that are present in every mammalian tissue, and their functions within the body are widespread and determined by their molecular structure.

The GAG molecules are long unbranched polysaccharides containing a repeating disaccharide unit. The disaccharide units contain either of two modified sugars, N-acetylgalactosamine (GalNAc) or N-acetylglucosamine (GlcNAc), and a uronic acid such as glucuronate (GlcA) or iduronate (IdoA), or a galactose residue. GAGs are highly negatively charged molecules, with an extended conformation that imparts high viscosity to the solution in which they reside.

The individual members of the GAG family are well established. There are six separate GAGs: hyaluronic acid, chondroitin sulfates, dermatan sulfates, keratan sulfates, heparan sulfates, and heparin. In supplement and food-science contexts, the term "mucopolysaccharide" is most commonly applied to the sulfated members of this family — particularly chondroitin sulfate, dermatan sulfate, keratan sulfate, and heparan sulfate — as well as to hyaluronic acid (hyaluronan), which is unsulfated.

The structures of the sulfated mucopolysaccharides are outlined and their common and particular features are noted: all are normally attached to specific proteins by covalent linkages to form large complex molecules. A linkage region consisting of atypical neutral sugars that joins the carbohydrate chain to protein is common to all the sulfated mucopolysaccharides apart from keratan sulfate, and the formation of this region is strictly controlled by the specificities of the glycosyl transferases that form it.

The basic unit of acid mucopolysaccharides is a so-called mixed disaccharide consisting of glucuronic acid linked to N-acetyl-d-glucosamine. The most abundant mucopolysaccharide, hyaluronic acid, is composed of glucuronic acid and an amino sugar, N-acetyl glucosamine. Other carbohydrates of the connective tissue are chondroitin-4-sulfate (chondroitin sulfate A) and chondroitin-6-sulfate (chondroitin sulfate C).

In the plant kingdom, the term "mucopolysaccharide" has a distinct, broader meaning. Mucopolysaccharides (also called mucilage polysaccharides) are naturally occurring compounds present in plant cell walls, cyanobacteria, and intercellular cementing substances. Structurally, these polysaccharides are composed of various monosaccharide units and sugar derivatives, including galactose and uronic acids, which contribute to their functional diversity and bioactivity. A particularly notable example from the plant world is pectin. The present article focuses primarily on the animal-derived, GAG-type mucopolysaccharides that are used as dietary supplements.

2. Natural Sources and Biological Distribution

Historically, the function of GAGs was thought to be limited to cell hydration and structural scaffolding. However, evidence now suggests that GAGs play a key role in cell signaling, which modulates a wide range of biochemical processes. Some of these processes include regulation of cell growth and proliferation, promotion of cell adhesion, anticoagulation, and wound repair, among many more.

GAGs are distributed across virtually all mammalian tissues. Mucopolysaccharides are present in synovial fluid, the natural lubricant found in joints, facilitating smooth movement. They are components of the skin and the cornea of the eye, contributing to their hydration and structural integrity. Glycosaminoglycans are capable of holding a large amount of water, thus maintaining the turgidity of the skin.

Hyaluronic acid (HA) is an important component of the extracellular matrix, with loss starting at 25 years old. There are six types of GAGs: chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, heparin, and HA. Unlike other GAGs, HA is nonsulfated and occurs in a vast number of configurations and shapes, depending on size, salt concentration, pH, and associated cations.

Commercial supplement sources are primarily animal in origin. Major sources of GAGs for nutritional supplements include cartilage, shellfish, and plants. Crude forms include varying grades of cartilage powders (usually from beef trachea), dried mussels, or seaweed extracts. Historically, mucopolysaccharides have been extracted from animal sources such as shark cartilage and bovine trachea for use in nutritional supplements and functional foods.

Marine invertebrates represent a particularly concentrated source. Sea cucumber, from a nutritional viewpoint, is an ideal tonic food containing 10–16% mucopolysaccharides — substances that are used to build cartilage. Sea cucumbers are a potential source of high value-added compounds with therapeutic properties such as triterpene glycosides, carotenoids, bioactive peptides, vitamins, minerals, fatty acids, collagens, gelatins, chondroitin sulfates, and amino acids.

3. Common Supplement Forms and Preparations

Mucopolysaccharides, now known as glycosaminoglycans (GAGs), are available in crude and purified forms. Each category has distinct characteristics relevant to potency and bioavailability.

• Crude preparations: Crude forms include varying grades of cartilage powders (usually from beef trachea), dried mussels, or seaweed extracts. The availability of active components (GAGs) is not well known for each crude preparation, but they still represent a useful dietary source for GAGs.
• Purified chondroitin sulfate: Purified chondroitin sulfates are available; their absorption has been studied and shown to be nearly complete. Purified pharmaceutical-grade preparations are available in Europe as approved drugs. Chondroitin sulfate (CS) is a symptomatic slow-acting drug for osteoarthritis (SYSADOA), and there is a CS formulation approved as a drug in Europe, with efficacy and safety demonstrated by clinical trials in osteoarthritic patients.
• Hyaluronic acid (HA): Available for oral ingestion, topical application, and injectable use. In mammals, HA is synthesized by three types of HA synthases (HAS): HAS1, HAS2, and HAS3. HAS1 and HAS2 proteins form high molecular weight HA (around 600–1200 kDa), while HAS3 possesses the highest activity and polymerizes into low molecular weight HA (around 5–50 kDa).
• Papain-hydrolyzed concentrates: Some commercial mucopolysaccharide supplements use naturally occurring glycosaminoglycans in a concentrate extracted through papain hydrolysis.
• Sea cucumber preparations: Extracts of desired sea cucumber materials are put into easy-to-consume formats, such as capsules (hard and soft gelatin) and tablets.

4. Traditional and Historical Use

While the chemical isolation of GAGs is a 20th-century achievement, the dietary and medicinal traditions that relied on mucopolysaccharide-rich substances have ancient roots.

4.1 Traditional Chinese Medicine

According to the Ming dynasty account (1368–1644), sea cucumbers were known as "haishen," or "ocean ginseng," since they had the same medical qualities as ginseng. Within the framework of Traditional Chinese Medicine, sea cucumbers have been utilized as a revitalizing agent to treat skeletal and joint weakness, especially that associated with age-related inflexibility, renal system abnormalities, sexual disorders, dry-stool constipation, poor lipid digestion, and circulatory complications.

Sea cucumber was listed as a medicinal agent in the Bencao Congxin (New Compilation of Materia Medica) by Wu Yiluo in 1757. The popular Chinese name for sea cucumber is haishen, which means, roughly, "ginseng of the sea."

Since the era of the Ming dynasty kings, people in China have used sea cucumbers as a useful and effective medicine. The species Stichopus japanicus was employed for treating kidney problems, constipation, pulmonary tuberculosis, anemia, and diabetes. The viscera of sea cucumber were also used for treating epilepsy, and its intestines were considered to heal stomach pains and duodenal ulcers.

In Traditional Chinese Medicine, sea cucumbers have been used as a general tonic, as a treatment for skeletal and joint weakness including that linked with age-associated inflexibility, kidney system disorders, impotence, and dry-stool constipation.

4.2 Broader Asian Traditions and Culinary Use

Sea cucumbers are mainly used in Asian cuisines for centuries. Following a complicated process of preparation, the dried meat can be used in soups, stir-fried dishes, and also be pickled. A traditional Chinese preparation is to poach the sea cucumber and cover it with a thick sauce of garlic, ginger, onion, and soy sauce. These marine organisms have also been used for traditional medicinal purposes since ancient times.

Sea cucumbers have long been used as food and traditional medicine in Asian countries, with Stichopus hermanni, Thelenota ananas, Thelenota anax, Holothuria fuccogilva, and Actinopyga mauritiana as the most highly-valued species.

4.3 Bone Broth and Cartilage-Based Remedies

Historically, substances rich in mucopolysaccharides — such as extracts from animal cartilage, sea cucumbers, and certain plants — were used in remedies aimed at promoting joint health, skin vitality, and overall wellness. Ancient Chinese and Ayurvedic medicine incorporated cartilage soups and broths, believed to support mobility and rejuvenation, centuries before the science behind mucopolysaccharides was understood.

4.4 Emergence in Modern Medical Use

Medicinal use of these compounds gained prominence in the early 20th century, particularly with the isolation of chondroitin sulfate and hyaluronic acid from animal tissues. Pharmaceutical-grade heparin, itself a GAG, has been in clinical use for decades. Heparin, prepared from pig intestine, is currently in widespread use as an anticoagulant drug with over 100 metric tons used annually.

5. Key Constituents and Active Compounds

When the term "mucopolysaccharide" is used in the supplement context, it refers to a family of related molecules, each with distinct chemical structures and proposed activities.

5.1 Chondroitin Sulfate (CS)

CS is a sulfated GAG and one of the major components of joint cartilage. Some effects of this GAG include acting as an anti-inflammatory, stimulating synthesis of proteoglycans and hyaluronic acid, and inhibiting the synthesis of proteolytic enzymes that cause cartilage matrix damage and death of chondrocytes.

5.2 Hyaluronic Acid (HA / Hyaluronan)

HA is the only non-sulfated member of the GAG family that appears prominently in supplements. Hyaluronic acid is composed of glucuronic acid and an amino sugar, N-acetyl glucosamine. Its most notable property is water-binding: glycosaminoglycans are capable of holding a large amount of water, thus maintaining the turgidity of the skin.

5.3 Heparan Sulfate and Heparin

Heparan sulfate (HS), dermatan sulfate (DS), and heparin are natural glycosaminoglycans which are linear polysaccharides, heterogeneous in both sequence and length. GAGs carry out many functions in the body; the most notable is control of coagulation, but GAGs also affect lipid metabolism, inflammation, cell attachment, migration, invasion, and differentiation.

5.4 Dermatan Sulfate and Keratan Sulfate

According to the type of hexosamine and glycosidic linkage in the disaccharide repeating units, GAGs are divided into five main types: nonsulfated GAGs, such as hyaluronic acid (HA), and sulfated GAGs, including heparin and heparan sulfate (HS), chondroitin sulfate (CS), dermatan sulfate (DS), and keratan sulfate (KS).

6. Mechanisms of Action

Mucopolysaccharides/GAGs exert their biological effects through multiple complementary pathways:

6.1 Structural and Water-Binding Functions

Proteoglycans (the updated name for mucopolysaccharide complexes) are a combination of long chains of special, modified sugars (oligosaccharides) known as glycosaminoglycans (GAGs) that are lashed together much like scaffold structures by special, modified proteins. This scaffolding maintains tissue architecture and hydration.

6.2 Cell Signaling

GAGs are a family of linear and negatively charged polysaccharides that exist ubiquitously on the human cell surface as well as in the extracellular matrix. GAGs interact with a wide range of proteins, including proteases, growth factors, cytokines, chemokines, and adhesion molecules, enabling them to mediate many physiological processes, such as protein function, cellular adhesion, and signaling.

6.3 Cartilage and Joint-Specific Mechanisms

The effect of chondroitin sulfate in people with osteoarthritis is likely the result of a number of reactions including its anti-inflammatory activity, the stimulation of the synthesis of proteoglycans and hyaluronic acid, and the decrease in catabolic activity of chondrocytes, inhibiting the synthesis of proteolytic enzymes, nitric oxide, and other substances that contribute to damage the cartilage matrix and cause death of articular chondrocytes.

Glucosamine has been shown to inhibit phospholipase A2, matrix metalloproteinases (MMPs), and aggregases, whereas chondroitin has been shown to significantly decrease collagenolytic activity and to induce proteoglycan production. Glucosamine has also been shown to increase aggrecan and collagen type II, which are components of the extracellular matrix. Because of these mechanisms, it is thought that these two nutritional supplements work together synergistically in managing OA and other conditions affecting joints and cartilage.

6.4 Anticoagulant Mechanisms

The glycosaminoglycans heparan sulfate, dermatan sulfate, and heparin are important anticoagulants that inhibit clot formation through interactions with antithrombin and heparin cofactor II. This specific interaction leads to a conformational change in antithrombin, resulting in its potent inhibition of thrombin and other serine proteases, and heparin's anticoagulant activity.

6.5 Proteoglycan Biosynthesis Support

Chondrocytes must take dietary carbohydrates (sugars) and, with enough energy, protein, vitamins, and minerals, convert those sugars into the modified ones needed for GAG synthesis. A GAG must then be strung together, cast out into the extracellular matrix, worked over by enzymes that control three-dimensional structure of GAG and collagen chains, merged with other GAGs and collagen to form desired structures, and then "cured" by other enzymes to harden and solidify the new connective tissue.

7. Scientific Evidence by Area of Use

7.1 Osteoarthritis and Joint Pain

Overview of evidence: Joint health, particularly osteoarthritis (OA) of the knee, is the most extensively studied indication for chondroitin sulfate and related GAG supplements. The evidence is mixed but partially positive, varying by patient subgroup and preparation.

The GAIT Trial (NEJM, 2006): Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis. Investigators randomly assigned 1,583 patients with symptomatic knee osteoarthritis to receive 1,500 mg of glucosamine daily, 1,200 mg of chondroitin sulfate daily, both glucosamine and chondroitin sulfate, 200 mg of celecoxib daily, or placebo for 24 weeks.

Glucosamine and chondroitin sulfate alone or in combination did not reduce pain effectively in the overall group of patients with osteoarthritis of the knee. Exploratory analyses suggest that the combination of glucosamine and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain.

GAIT structural sub-study (24 months): A 24-month, double-blind, placebo-controlled sub-study of the GAIT enrolled 572 patients with knee OA. Patients continued to receive glucosamine 500 mg three times daily, CS 400 mg three times daily, the combination of glucosamine and CS, celecoxib 200 mg daily, or placebo over 24 months. This extension assessed structural outcomes (joint space width), though definitive structural benefit was not clearly established.

2025 Systematic Review (MDPI Nutrients): Most studies focused on osteoarthritis and joint pain, with over 90% of efficacy studies reporting positive outcomes and most safety studies indicating minimal or no adverse effects. However, the authors noted that the anti-inflammatory and cartilage-preserving properties of glucosamine and chondroitin were evident in the review.

Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain. Consistent dosing strategies and favorable safety profiles across a diverse range of studies support their continued use in clinical practice, but further research is needed related to other disease states.

Preclinical (animal) evidence: A systematic review covering 2000–2021 found that preclinical studies showed great heterogeneity among experimental designs and their outcomes. Generally, the evaluated nutraceuticals, alone or in combination, did not seem to prevent subchondral bone changes, synovial inflammation, or osteophyte formation. However, further experimental studies may be needed to evaluate their effect at those levels.

Regulatory divergence: Experts are divided over the effectiveness of chondroitin, with the American College of Rheumatology recommending against its use for osteoarthritis of the hip or knee and issuing only a conditional recommendation for its use in treating osteoarthritis of the hand. By contrast, the European Society of Clinical and Economic Aspects of Osteoarthritis recommends the use of pharmaceutical-grade chondroitin for osteoarthritis of the hand.

Evidence strength: Moderate for pain relief in moderate-to-severe knee OA, particularly when glucosamine and chondroitin sulfate are combined; weak for structural disease modification. Results are mixed across studies, with high placebo response rates complicating interpretation.

7.2 Skin Health and Wound Healing

Oral hyaluronic acid: A double-blind, randomized clinical trial with 129 female participants, covering young and elderly groups and different skin types, was conducted to assess the efficacy of orally administered HA on skin health. Oral administration of HA significantly promoted skin hydration after 2–8 weeks among both young and elderly groups. Skin tone improvement was observed after 4–8 weeks, while an increase in epidermal thickness was noted after 12 weeks. This study provides direct evidence supporting the clinical efficacy of oral intake of HA in promoting skin health.

Topical applications: HA possesses healing properties and thus is an important tool in the treatment of acute wounds such as burns and diabetic foot. These properties contribute to the restoration of skin barrier function, modulation of oxidative stress and inflammation, and promotion of extracellular matrix remodeling. Preclinical evidence supports the efficacy of sulfated HA in reducing dryness, irritation, and inflammatory responses in atopic dermatitis, psoriasis, and acne. Preliminary findings also suggest potential benefits in wound healing and skin barrier repair.

However, current evidence remains limited to preliminary studies. Future controlled clinical trials are required to confirm efficacy, optimize formulations, and establish standardized treatment protocols.

Evidence strength: Moderate for oral HA and skin hydration; topical HA is well-supported for wound care in clinical practice; sulfated HA modifications remain at a preliminary/preclinical stage.

7.3 Sea Cucumber-Derived Mucopolysaccharides

Marine organisms (sea cucumbers) have been used for traditional medicinal purposes since ancient times, and recently, many studies provide scientific evidence that sea cucumber contains multitude biologically active materials that provide health benefit effects such as antioxidant, antibacterial, antifungal, antiviral, anti-inflammatory activities, neuroprotective activities, etc.

Saponin, cerebrosides, acid mucopolysaccharide, peptides, and fucosylated chondroitin sulfate (FCS) are five of the most-studied compounds derived from sea cucumber that have proven anticancer activities in animal models. Saponins accounted for 72% of sea cucumber studies in the tumor and cancer management field.

Studies in humans are quite limited, however. Preliminary findings suggest a sea cucumber extract may help chronic gingivitis, but clinical evidence for its use in any condition is lacking.

Evidence strength: Weak to preliminary in humans. Animal and in vitro studies are numerous, but robust human clinical trials are largely absent for sea cucumber-derived mucopolysaccharide preparations specifically.

7.4 Cardiovascular and Coagulation Effects

Heparan sulfate (HS), dermatan sulfate (DS), and heparin are natural glycosaminoglycans. GAGs carry out many functions in the body; the most notable is control of coagulation, but GAGs also affect lipid metabolism, inflammation, cell attachment, migration, invasion, and differentiation.

GAGs interact with a wide range of proteins, including proteases, growth factors, cytokines, chemokines, and adhesion molecules, enabling them to mediate many physiological processes, such as protein function, cellular adhesion, and signaling. GAG-protein interactions participate in and intervene in a variety of human diseases, including cardiovascular disease, infectious disease, neurodegenerative diseases, and tumors.

Pharmaceutical heparin (a GAG) is a well-established drug: unfractionated heparin, low-molecular-weight heparin, and heparin-derived drugs are used clinically to treat coagulatory disorders. However, dietary supplement forms of mucopolysaccharides are not equivalent to pharmaceutical heparin.

Evidence strength: Robust for pharmaceutical-grade heparin/heparin derivatives in anticoagulation; evidence for cardiovascular benefit from OTC mucopolysaccharide supplements (chondroitin, HA) is limited to observational and mechanistic data.

8. Body Systems and Health Areas Associated with Mucopolysaccharides

• Musculoskeletal system: Cartilage maintenance, joint lubrication, and osteoarthritis management are the primary associations. Glucosamine hydrochloride, chondroitin sulfate, and hyaluronic acid are considered symptomatic slow-acting drugs for OA (SYSADOA), and some have also shown a disease-modifying osteoarthritis drug (DMOAD) effect, showing a delay in the progression of OA, reducing pain, stiffness, and joint swelling.
• Integumentary system (skin): Skin aging goes beyond a chronological process and also results from extrinsic factors. Hyaluronic acid is an important component of the extracellular matrix, with loss starting at 25 years old.
• Vascular system: GAGs also affect lipid metabolism, inflammation, cell attachment, migration, invasion, and differentiation, and play a key role as anticoagulants, preventing coagulation from occurring when it is not required.
• Wound healing and tissue repair: Evidence now suggests that GAGs play a key role in cell signaling, which modulates a wide range of biochemical processes — including wound repair.
• Ophthalmological: Mucopolysaccharides are components of the cornea of the eye, contributing to their hydration and structural integrity.

9. Pharmacokinetics: Absorption, Distribution, and Bioavailability

A key question for GAG supplements is whether orally administered molecules are absorbed in biologically meaningful amounts, given their large molecular size.

Chondroitin sulfate: Pharmacokinetic studies performed on humans and experimental animals after oral administration of chondroitin sulfate revealed that it can be absorbed orally. Chondroitin sulfate shows first-order kinetics up to single doses of 3,000 mg. After administration of a 4 g oral dose (Condrosulf), chondroitin sulfate plasma levels increased more than 200% in all subjects, with a peak concentration after 2 hours, with the increase reaching significance from 2 to 6 hours. It appears that exogenous chondroitin sulfate is absorbed as a high molecular mass polysaccharide together with derivatives resulting from partial depolymerization and/or desulfation.

Pharmacokinetic studies have shown that oral exogenous CS is absorbed as several metabolites, and the active moiety has not yet been identified. It is thus difficult to establish bioequivalence from plasma concentration-versus-time curves.

The average adult metabolizes about 250 mg of glycosaminoglycans each day, with 10% of the metabolites excreted in urine. Chondroitin sulfate accounts for 60% of the glycosaminoglycans in human urine.

Hyaluronic acid: The absorption of hyaluronans and chondroitin sulfate is likely negatively affected by their high molecular weight. Nevertheless, many published papers have reported significant improvements in symptoms and articular functionality in patients taking these compounds. This apparent dichotomy between absorption and efficacy has been studied by comparing the clinical evidence for the bioavailability of hyaluronic acid with that of its precursor N-acetyl glucosamine.

10. Dosage Forms and Dosages Reported in Clinical Studies

The following dosages are those reported in identified clinical research sources and do not represent recommendations:

• Chondroitin sulfate (oral, OA): Chondroitin sulfate has been administered orally for treatment of arthritis at a dosage of 800 to 1,200 mg/day. Positive results often require several months to manifest, and a posttreatment effect has been observed.
• Chondroitin sulfate + glucosamine (GAIT trial): The GAIT sub-study used glucosamine 500 mg three times daily, CS 400 mg three times daily, or the combination, over 24 months.
• Glucosamine + chondroitin + HA (liquid mixture, knee OA): Subjects were allocated to administer either a bottle of 20 mL supplement mixture (50 mg HA plus 750 mg glucosamine plus 250 mg chondroitin) or placebo once daily for 8 weeks.
• Chondroitin sulfate (pharmacokinetic, healthy volunteers): Chondroitin sulfate was orally administered to healthy volunteers in a single daily dose of 0.8 g and in two daily doses of 0.4 g. The results showed that both forms of administration determined a significant increase in plasma concentration.
• Commercial mucopolysaccharide concentrate capsules: Adults: Take 1 or 2 capsules 3 times daily before meals or as directed by a physician (as reported on one commercial preparation).

11. Safety Considerations and Drug Interactions

11.1 General Tolerability

Chondroitin sulfate seems to have no serious side effects. Among the most common side effects are stomach pain, nausea, and other digestive tract symptoms. Potential adverse reactions associated with chondroitin sulfate include alopecia, constipation, diarrhea, epigastralgia, extrasystoles, eyelid edema, lower limb edema, and skin symptoms. Chondroitin sulfate may also exacerbate asthma.

11.2 Animal Source Contamination Risk

Unless the chondroitin sulfate is pharmaceutical grade, it has the potential to transmit infections with bacteria, viruses, or prions. This risk applies to any mucopolysaccharide concentrate derived from non-pharmaceutical animal tissue.

11.3 Anticoagulant Interaction (Warfarin)

Chondroitin sulfate taken with warfarin and possibly other medications that prevent blood clots (anticoagulants) may increase the risk of bleeding; therefore, people taking anticoagulants should avoid chondroitin sulfate. The most significant and well-documented risk arises when chondroitin is taken concurrently with anticoagulant medications such as warfarin. Multiple reports and studies indicate that taking chondroitin (especially with glucosamine) can potentiate the effects of warfarin, leading to an elevated International Normalized Ratio (INR), a measure of blood clotting time. The mechanism underlying this interaction remains incompletely established.

11.4 Intrinsic Anticoagulant Properties

Whilst chondroitin sulfate was found to have minimal anticoagulant activity, increasing sulfation levels produced an anticoagulant response, mediated through heparin cofactor II. This is a dose- and structure-dependent property, not equivalent to the effect of pharmaceutical heparin at supplement doses.

11.5 Oversulfated Chondroitin Sulfate Contamination (Pharmaceutical Context)

In 2008, there were many adverse events, including fatalities, associated with the administration of certain preparations of heparin. Analysis of the heparin preparations associated with these events found a contaminating material, oversulfated chondroitin sulfate (OSCS). This contaminating material was found to interact with the contact system in plasma through activation of prekallikrein, which cleaved high molecular weight kininogen, leading to the formation of bradykinin — a potent vasodilator causing a hypotensive response. This event is specifically relevant to heparin pharmaceutical products and not to standard oral chondroitin sulfate supplements, but underscores the importance of purity standards in GAG products.

11.6 Renal Impairment

In 22 patients with renal failure, chondroitin sulfate half-life was prolonged, but it could be administered for clot prevention during hemodialysis in this population.

11.7 Pregnancy and Lactation

Information regarding safety and efficacy in pregnancy and lactation is lacking.

References

• Biochemistry, Glycosaminoglycans — StatPearls, NCBI Bookshelf
• Glycosaminoglycans and Proteoglycans — The Medical Biochemistry Page
• Glycosaminoglycan — Encyclopædia Britannica
• The structure and metabolism of mucopolysaccharides (glycosaminoglycans) and the problem of the mucopolysaccharidoses — The American Journal of Medicine (1969)
• The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review — MDPI Nutrients (2025)
• The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review — PMC
• Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis — New England Journal of Medicine (2006)
• The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the GAIT — PubMed
• Clinical Efficacy and Safety of Chondroitin Combined with Glucosamine in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis — PubMed
• Glucosamine and Chondroitin Sulfate: Is There Any Scientific Evidence for Their Effectiveness as Disease-Modifying Drugs in Knee Osteoarthritis Preclinical Studies? — PMC
• Improved Joint Health Following Oral Administration of Glycosaminoglycans with Native Type II Collagen in a Rabbit Model of Osteoarthritis — PMC
• Benefits of topical hyaluronic acid for skin quality and signs of skin aging: From literature review to clinical evidence — PMC
• Oral administration of hyaluronic acid to improve skin conditions via a randomized double-blind clinical test — PMC
• Sulfated Hyaluronan in Dermatology: What's New? Overview of Evidence in Specific Dermatological Diseases — PMC
• Glycosaminoglycan-Protein Interactions and Their Roles in Human Disease — PMC
• Glycosaminoglycan Neutralization in Coagulation Control — PMC / Arteriosclerosis, Thrombosis, and Vascular Biology
• Recent progress and applications in glycosaminoglycan and heparin research — PMC
• In Vivo and Clinical Studies of Sea Cucumber-Derived Bioactives for Human Health and Nutrition — Frontiers in Marine Science (2022)
• Medicinal and health benefit effects of functional sea cucumbers — PMC
• Therapeutic Potential of Sea Cucumber-Derived Bioactives in the Prevention and Management of Brain-Related Disorders — PMC
• Sea Cucumber — Memorial Sloan Kettering Cancer Center Integrative Medicine
• Sea Cucumber: Food and Medicine — Institute for Traditional Medicine
• Chondroitin Sulfate — Merck Manual Consumer Version
• Chondroitin Uses, Benefits & Dosage — Drugs.com Natural Products
• Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers — PubMed
• Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate — PubMed
• The effect of increasing the sulfation level of chondroitin sulfate on anticoagulant specific activity and activation of the kinin system — PubMed
• Oversulfated chondroitin sulfate: impact of a heparin impurity associated with adverse clinical events — PubMed
• Hyaluronic Acid-Based Scaffolds as Potential Bioactive Wound Dressings — PMC
• Mucopolysaccharides/Chondroitin Sulfates as Dietary Supplements — Vitaflex Equine Clinical Research
• Polysaccharides Obtained from Vegetables: An Effective Source of Alternative Excipient — PMC
• Plant bioactive compounds: extraction, biological activities, nutritional aspects, and human health benefits — PMC